Last quarter (Q4 2023), Black Diamond Therapeutics's total revenue was $334.00K, an increase of Infinity% from the same quarter last year. In Q4, Black Diamond Therapeutics's net income was $-19.41M. See Black Diamond Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 1.14M	$ 1.14M	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 1.14M	$ 1.14M	-	-	-	-
Operating Expense	$ 86.46M	$ 86.46M	$ 92.83M	$ -126.87M	$ 69.57M	$ 29.33M
Operating Income	$ -86.46M	$ -86.46M	$ -92.83M	$ -126.87M	$ -69.57M	$ -29.33M
Net Non Operating Interest Income Expense	-	-	-	-	$ 4.04M	$ 461.00K
Other Income Expense	$ -4.02M	$ -4.02M	$ -1.66M	$ -1.28M	$ -1.72M	$ -6.39M
Pretax Income	$ -82.44M	$ -82.44M	$ -91.17M	$ -125.60M	$ -67.25M	$ -35.26M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	$ -2.25M	-	-	-
Net Income Common Stockholders	$ -82.44M	$ -82.44M	$ -91.17M	$ -125.60M	$ -67.25M	$ -35.26M
Basic EPS	$ -1.91	$ -1.88	$ -2.52	$ -3.47	$ -2.05	$ -1.08
Diluted EPS	$ -1.91	$ -1.88	$ -2.52	$ -3.47	$ -2.05	$ -1.08
Basic Average Shares	$ 175.82M	$ 43.95M	$ 36.33M	$ 36.19M	$ 32.91M	$ 32.64M
Diluted Average Shares	$ 175.82M	$ 43.95M	$ 36.33M	$ 36.19M	$ 32.91M	$ 32.64M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 86.46M	$ 86.46M	$ 92.83M	$ -126.87M	$ 69.57M	$ 29.33M
Net Income From Continuing And Discontinued Operation	$ -82.44M	$ -82.44M	$ -91.17M	$ -125.60M	$ -67.25M	$ -35.26M
Normalized Income	$ -48.64M	$ -65.13M	-	-	$ -67.25M	$ -28.86M
Interest Expense	-	-	-	-	$ 1.00K	$ 0.00
EBIT	$ -82.44M	$ -82.44M	$ -91.17M	$ -125.60M	$ -67.25M	$ -35.26M
EBITDA	$ -82.00M	$ -82.00M	$ -90.13M	$ -123.20M	$ -67.20M	$ -35.21M

Currency in USD

Black Diamond Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing